A next-generation phacoemulsification platform (Stellaris Elite with Adaptive Fluidics technology, Bausch + Lomb) is designed to improve stability of the eye during cataract surgery. Early clinical results suggest the system enables better maintenance of anterior chamber depth, which is especially useful for eyes with shallow chamber depth or high posterior pressure as it provides overall stability while reducing phaco energy used.
“The concept of adaptive fluidics is to be able to increase the chamber pressure during occlusion to reduce the effect of the post-occlusion surge,” said Mitchell Shultz, MD, cataract, cornea, and refractive surgeon, Shultz Chang Vision, Los Angeles.
“When material is aspirated, there is less fluctuation of the anterior chamber,” he explained. “Adaptive fluidics enables the user to increase anterior chamber pressure, which, in turn, facilitates the ability to increase the vacuum pressure setting. By getting to higher pressure and maintaining stability, we are able to reduce the amount of phaco energy used intraoperatively.”
Dr. Shultz discussed results of benchtop comparisons, as well as his clinical experience. The bench trial compared the performance of this system with its adaptive fluidics and another platform (Centurion with Active Infusion, Alcon Laboratories). He uses both platforms, in addition to having prior experience with another system (WhiteStar Signature, Johnson & Johnson Vision).